Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
2023年12月29日 - 10:00PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic Surgical System, today announced the
entry into a definitive agreement for the immediate exercise of
certain outstanding preferred investment options to purchase up to
an aggregate of 1,685,682 shares of common stock, having exercise
prices ranging from $2.075 to $3.19 per share, issued by Microbot
in October 2022 and June 2023, at a reduced exercise price of $1.62
per share. The shares of common stock issuable upon exercise of the
preferred investment options are registered pursuant to an
effective resale registration statement on Form S-1 (File No.
333-273207). The closing of the offering is expected to occur on or
about January 3, 2024, subject to satisfaction of customary closing
conditions.
H.C. Wainwright & Co. is acting as the exclusive placement
agent for the offering.
In consideration for the immediate exercise of
the preferred investment options for cash, Microbot will issue new
unregistered series E preferred investment options to purchase up
to 1,685,682 shares of common stock. The new series E preferred
investment options will have an exercise price of $1.50 per share,
will be exercisable immediately upon issuance and have a term equal
to five and one-half years from the date of issuance.
The gross proceeds to the Company from the
exercise of the preferred investment options are expected to be
approximately $2.73 million, prior to deducting placement agent
fees and offering expenses. The Company intends to use the net
proceeds from the offering for the continued development,
commercialization and regulatory activities for the Company’s
LIBERTY® Robotic System, expansion and development of additional
applications derived from the Company’s existing IP portfolio, and
for working capital and other general corporate purposes.
The new series E preferred investment options
described above were offered in a private placement pursuant to an
applicable exemption from the registration requirements of the
Securities Act of 1933, as amended (the “1933 Act”), and, along
with the shares of common stock issuable upon exercise, have not
been registered under the 1933 Act, and may not be offered or sold
in the United States absent registration with the Securities and
Exchange Commission (“SEC”) or an applicable exemption from such
registration requirements. Microbot has agreed to file a
registration statement with the SEC covering the resale of the
shares of common stock issuable upon exercise of the new series E
preferred investment options.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities in this
offering, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Endovascular Robotic Surgical
System aims to improve the way surgical robotics are being used in
endovascular procedures today, by eliminating the need for large,
cumbersome, and expensive capital equipment. The Company believes
the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is
available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, the timing and
completion of the offering; the satisfaction of customary closing
conditions related to the offering and the intended use of proceeds
therefrom, as well as market and other conditions, risks inherent
in the development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate LIBERTY,
whether the Company’s core business focus program and cost
reduction plan are sufficient to enable the Company to continue to
focus on its LIBERTY technology while it stabilizes its financial
condition and seeks additional working capital, any failure or
inability to recruit physicians and clinicians to serve as primary
investigators to conduct regulatory studies which could adversely
affect or delay such studies, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, disruptions resulting from new and ongoing
hostilities between Israel and the Palestinians, such as employees
of Microbot and its vendors and business partners being called to
active military duty, any lingering uncertainty resulting from the
COVID-19 pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michal
Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 8 2024 まで 9 2024
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 9 2023 まで 9 2024